Avience Biomedicals Ltd Share Price Jumps 90%: Stock Lists at ₹395.20 on NSE SME After IPO at ₹208

Avience Biomedicals Ltd (NSE SME: AVIENCE) delivered one of the standout SME debuts of 2026. The IPO was priced at ₹208 per share, with a price band of ₹196 to ₹208. On June 25, 2026, the stock listed at ₹395.20 on NSE SME Emerge, a gain of approximately 90% over the issue price. The debut reflects strong market confidence in the Noida-based IVD and medical devices manufacturer, backed by massive subscription demand across all investor categories.

IPO Details at a Glance

The Avience Biomedicals IPO consisted of an entirely fresh issue of 14,53,800 shares with a face value of ₹10, totalling ₹30.24 crore. The subscription window ran from June 18 to June 22, 2026, with allotment finalised on June 23, 2026.

IPO Structure – Key Numbers:

• Issue Size: ₹30.24 crore (fresh issue only)
• Price Band: ₹196–₹208 per share
• Lot Size: 600 shares
• Minimum Retail Investment: ₹2,49,600 (1,200 shares)
• Registrar: Skyline Financial Services Pvt. Ltd.
• Lead Manager: Fintellectual Corporate Advisors Pvt. Ltd.
• Listing Date: June 25, 2026, NSE SME Emerge

Subscription Demand: Massively Oversubscribed

The market’s appetite for this SME IPO was exceptional. The Avience Biomedicals IPO was subscribed 385.32 times overall by the close of Day 3 on June 22, 2026. The retail (individual investor) category subscribed 401.36 times, QIB subscribed 196.77 times, and the NII category led with 597.23 times subscription. That level of NII demand signals very strong conviction from high-net-worth participants in Avience Biomedicals Ltd. 

🔔 SME IPO Listing Update 📈

📍 Avience Biomedicals SME IPO
📊 Listed at ₹395.2 on NSE vs issue price ₹208
🚀 Premium: +90%

💰 Investment (2 lots): ₹2,49,600
💵 Profit (2 lots): ₹2,24,640

🎉 Congratulations to all who got allotment! 🚀

— IPO Ji ® (@ipoji_) June 25, 2026

About Avience Biomedicals Ltd: What the Company Does

Avience Biomedicals is an ISO-certified company involved in the manufacture, supply, and export of molecular diagnostics solutions, focusing on biotechnology, genomics, and the IVD sector. Its products are targeted at Pathology Labs, Microbiology Labs, Hospitals, and Research Centres, both in India and overseas.

The product portfolio includes rapid test kits, molecular diagnostic solutions, biochemistry analysers, reagents, haematology analysers, and selected medical devices such as oxygen concentrators. The manufacturing facility is located in Noida, Uttar Pradesh.

Financials: Revenue Nearly Doubled in One Year

The numbers behind Avience Biomedicals Ltd are hard to ignore. The company reported revenue of ₹45.97 crore in FY25, up from ₹24.37 crore in FY24. Profit jumped to ₹7.23 crore in FY25 from ₹2.14 crore in FY24. For the ten months ended January 2026, total income stood at ₹41.94 crore, with PAT of ₹5.74 crore and EBITDA of ₹10.34 crore. Revenue growth of ~89% year-on-year is exactly the kind of trajectory SME investors look for.

Use of IPO Proceeds

From the net IPO proceeds, Avience Biomedicals plans to utilise ₹15.95 crore for capex on setting up a new manufacturing facility at YEIDA, UP, ₹8.25 crore for working capital, and the rest for general corporate purposes. The YEIDA plant expansion directly targets production scale-up to meet growing B2B and B2G demand.

Related Stocks to Watch in the SME Diagnostics Space

Other NSE SME-listed healthcare and diagnostics stocks worth tracking alongside Avience Biomedicals Ltd:

• Q-Line Biotech, a diagnostics-focused SME IPO listed in May 2026, raised ₹214 crore
• Thyrocare Technologies (NSE: THYROCARE) diagnostic chain, established, listed peer
• Metropolis Healthcare (NSE: METROPOLIS) pan-India diagnostics network

Avience Biomedicals Ltd’s 90% listing pop and near-doubling revenue trajectory make it a noteworthy addition to the NSE SME healthcare segment on June 25, 2026.

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.